SLC41A3 and hepatocellular carcinoma: In this study, we found that SLC41A3, SEC61A1, LRP4, PPM1G, and HSP90AA1 were abnormally expressed in responder and nonresponder tissues from patients with HCC who were treated with sorafenib.